Work

First-line therapy with rituximab vs. rituximab-CHOP in post-transplant monomorphic diffuse large B-cell lymphoma (DLBCL): Long-term real-world evidence from the spanish group of lymphoma (GELTAMO)

Year: 2025
Type: conference-abstract
Source: Blood
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: closed
OpenAlex ID: W4417005116
Cites:
Cited by:
Related to: